CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Monte Rosa Therapeutics Presents Plans for Four Phase 2 Trial Starts in 2026

By Public Technologies
  • Monte Rosa Therapeutics expects cash runway into 2029, covering multiple anticipated Phase 2 studies across its three clinical programs.
  • Potential collaboration payments exceed $350 million over the next 24 months, following more than $400 million received over the past three years.
  • Novartis is conducting Phase 2a/b trials of MRT-6160 in Sjögren's disease and psoriatic arthritis; additional Phase 2 studies are expected.
  • MRT-8102 Phase 2 trials are planned for gout in Q4 2026, with coronary artery disease and hidradenitis suppurativa studies in H1 2027.
  • MRT-2359's Phase 2 trial in AR-mutant metastatic castration-resistant prostate cancer is ongoing, with an update expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.